{{Rsnum
|rsid=11748431
|Gene=FLT4
|Chromosome=5
|position=180641741
|Orientation=plus
|GMAF=0.146
|Gene_s=FLT4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.1 | 35.4 | 57.5
| HCB | 0.0 | 2.9 | 97.1
| JPT | 0.0 | 4.4 | 95.6
| YRI | 3.4 | 25.9 | 70.7
| ASW | 1.8 | 12.3 | 86.0
| CHB | 0.0 | 2.9 | 97.1
| CHD | 0.9 | 5.5 | 93.6
| GIH | 4.0 | 29.0 | 67.0
| LWK | 3.6 | 23.6 | 72.7
| MEX | 0.0 | 29.3 | 70.7
| MKK | 8.3 | 40.4 | 51.3
| TSI | 5.9 | 32.4 | 61.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=23232491
|Title=A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}